Target intelligence / Profile preview

RNA polymerase I transcription factor RRN3 (RRN3)

Target
RRN3
Molecular classification
Transcription factor, RNA polymerase I-associated factor, HEAT repeat-containing protein
01

Overview

RNA polymerase I transcription factor RRN3 is a conserved transcription factor essential for the initiation of ribosomal RNA (rRNA) gene transcription by RNA polymerase I. RRN3 forms a transient complex with RNA polymerase I, enabling it to recognize and bind to the rDNA promoter during transcription initiation. Structurally, RRN3 contains HEAT repeats, mediates protein–protein interactions, and its function is regulated by phosphorylation, particularly at a conserved serine-rich surface patch. This phosphorylation prevents RRN3 from interacting with RNA polymerase I, thereby repressing rRNA synthesis and cell growth. RRN3 is conserved from yeast through mammals and is known as TIF-IA in humans. It does not bind DNA in a sequence-specific manner but instead facilitates assembly of the pre-initiation complex at rDNA promoters. Due to its pivotal role in ribosome production and cell proliferation, RRN3 is regarded as a potential therapeutic target, especially in hyperproliferative diseases like cancer[1][2][3][4].

Other names
TIF-IA (in humans)Rrn3RNA polymerase I-specific transcription initiation factor RRN3Transcription initiation factor IIA-related protein
02

Mechanism of action

Inhibition of RRN3 function would be expected to impair Pol I-mediated rRNA synthesis, suppressing ribosome production and cell proliferation[1][2][4]

03

Biological functions

Regulation of ribosomal RNA (rRNA) transcription initiationRibosome biogenesisRegulation of cell growth and proliferationMediating the interaction between RNA polymerase I and promoter DNA
04

Disease associations

Cancer (regulation of ribosome biogenesis is frequently altered in cancer)Other (perturbations in ribosomal biogenesis may play roles in additional proliferative diseases)
05

Safety considerations

Inhibition may cause cytotoxicity in highly proliferative cells, including non-cancerous tissues, due to the essential role of rRNA synthesis in cell growth
06

Interacting drugs

None currently approved or in clinical trials specifically targeting RRN3; research targeting rRNA transcription may affect this factor indirectly
07

Biomarkers

None currently established for patient selection or monitoring efficacy

Beyond the preview

Go deeper on RNA polymerase I transcription factor RRN3 (RRN3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA polymerase I transcription factor RRN3 (RRN3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call